3 false false false false false false false false false false true false false false false true true No description of principal activity 2025-01-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:USD 14815601 2025-01-01 2025-12-31 14815601 2025-12-31 14815601 2024-12-31 14815601 2024-01-01 2024-12-31 14815601 2024-12-31 14815601 2023-12-31 14815601 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 14815601 bus:Director1 2025-01-01 2025-12-31 14815601 core:WithinOneYear 2025-12-31 14815601 core:WithinOneYear 2024-12-31 14815601 core:ShareCapital 2025-12-31 14815601 core:ShareCapital 2024-12-31 14815601 core:RetainedEarningsAccumulatedLosses 2025-12-31 14815601 core:RetainedEarningsAccumulatedLosses 2024-12-31 14815601 bus:SmallEntities 2025-01-01 2025-12-31 14815601 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 14815601 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 14815601 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 14815601 bus:FullAccounts 2025-01-01 2025-12-31 14815601 bus:OrdinaryShareClass1 2025-12-31 14815601 bus:OrdinaryShareClass1 2024-12-31
COMPANY REGISTRATION NUMBER: 14815601

TRANSPIRE BIO UK LTD

Filleted Unaudited Financial Statements

31 December 2025

TRANSPIRE BIO UK LTD

Statement of Financial Position

31 December 2025

| 2025 | 2024
Note | $ | $

Current assets

Debtors | 6 | 15,868 | 46,517
Cash at bank and in hand | 174,000 | 20,110
| --------- | --------
| 189,868 | 66,627

Creditors: amounts falling due within one year | 7 | 1,074,403 | 248,587
| ------------ | ---------
Net current liabilities | 884,535 | 181,960
| --------- | ---------
Total assets less current liabilities | ( 884,535) | ( 181,960)
| --------- | ---------
Net liabilities | ( 884,535) | ( 181,960)
| --------- | ---------

Capital and reserves

Called up share capital | 8 | 122 | 122
Profit and loss account | ( 884,657) | ( 182,082)
| --------- | ---------
Shareholders deficit | ( 884,535) | ( 181,960)
| --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 27 March 2026 , and are signed on behalf of the board by:

DR X ZENG |
Director |

Company registration number: 14815601

TRANSPIRE BIO UK LTD

Notes to the Financial Statements

Year ended 31 December 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Regus Vision Park, Chivers Way, Histon, Cambridge, CB24 9AD.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the Companies Act 2006.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss. The financial statements are prepared in US Dollars, which is the functional currency of the entity.
Disclosure exemptions
The entity satisfies the criteria of being a qualifying entity as defined in FRS 102. Its financial statements are consolidated into the financial statements of Smoore Aero TEch HK Limited which can be obtained from Unit 1501-5 15/F, Fwd Financial Centre 308 Des Voeux Road, Central, Sheung Wan, Hong Kong, HK. As such, advantage has been taken of the following disclosure exemptions available under paragraph 1.12 of FRS 102: (a) No cash flow statement has been presented for the company. (b) Disclosures in respect of financial instruments have not been presented. (c) Disclosures in respect of share-based payments have not been presented. (d) No disclosure has been given for the aggregate remuneration of key management personnel.
Income tax
The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income. Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date. The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 3 (2024: 1 ).
5. Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However the nature of estimation means that actual outcomes could differ from the estimates. In the Director's opinion there are no significant judgements or key sources of uncertainty.
6. Debtors

| 2025 | 2024
| $ | $
Trade debtors | 15,617 | 10,872
Amounts owed by group undertakings and undertakings in which the company has a participating interest | – | 35,523
Other debtors | 251 | 122
| -------- | --------
| 15,868 | 46,517
| -------- | --------

7. Creditors: amounts falling due within one year

| 2025 | 2024
| $ | $
Trade creditors | 16,881 | 6,385
Amounts owed to group undertakings and undertakings in which the company has a participating interest | 953,767 | 185,068
Social security and other taxes | – | 572
Other creditors | 103,755 | 56,562
| ------------ | ---------
| 1,074,403 | 248,587
| ------------ | ---------

8. Called up share capital
Issued, called up and fully paid

| 2025 | 2024
| No. | $ | No. | $
Ordinary shares of $ 1 each | 122 | 122 | 122 | 122
| ---- | ---- | ---- | ----

9. Controlling party
The immediate parent company of Transpire Bio UK Ltd is TranspireBio HK Limited a company registered in Hong Kong. The company is owned 100% by the parent company which is situated at Unit1501-5 15/F, Fwd Financial Centre, 308 Des Voeux Road, Central, Sheung Wan, Hong King, HK.